Carl Zeiss Meditec AG
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Andreas Pecher
- Full Time Employees
- 5,784
- Sector
- Health technology
- Industry
- Medical specialties
- Address
- Göschwitzer Straße 51-52 Jena TH Germany 07745
- IPO Date
- Mar 20, 2000
- Website
- zeiss.de
- Similar Companies
- Business
- Carl Zeiss Meditec AG, a leading medical technology company listed on the MDAX and TecDAX indices of the German stock exchange (AFX.DE), develops and markets innovative technologies and application-oriented solutions for ophthalmology and microsurgery. The company offers one of the most comprehensive product portfolios in ophthalmology, including systems and consumables for cataract and corneal refractive surgery; diagnostic and therapeutic devices for managing chronic eye diseases such as glaucoma and retinal disorders; solutions for posterior eye segment diagnosis and treatment; and digitally connected workflow tools incorporating machine learning and artificial intelligence for data management and automation. In microsurgery, it provides complete visualization solutions for minimally invasive procedures in neurosurgery, ear-nose-throat surgery, spine surgery, plastic and reconstructive surgery, and dentistry. Founded in 2002 as a subsidiary of Carl Zeiss AG through the merger of ZEISS's ophthalmic business with laser technology maker Asclepion Meditec AG, the company is headquartered in Jena, Germany, with significant operations in over 50 countries, including major employee bases in the USA, Japan, Spain, France, India, and China. In April 2024, Carl Zeiss Meditec completed the acquisition of Dutch Ophthalmic Research Center (D.O.R.C.) from Eurazeo SE, integrating D.O.R.C.'s EVA NEXUS platform and vitreoretinal surgery portfolio to enhance its ophthalmic offerings, particularly in retina and posterior segment procedures, and to expand digitally connected end-to-end workflows for surgeons.
Company News
Carl Zeiss Meditec AG (CZMWY) Q3 2026 Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Q2 2026 Earnings Call Transcript
Carl Zeiss Meditec Q2 Earnings Call Highlights
Carl Zeiss Meditec AG (OTCMKTS:CZMWY) Sees Large Increase in Short Interest
Carl Zeiss Meditec: Bad Optics But With 'Buy' Potential
Carl Zeiss Meditec AG (OTCMKTS:CZMWY) Receives Average Recommendation of “Hold” from Analysts
Carl Zeiss Meditec AG (CZMWY) Q1 2026 Earnings Call Transcript
Carl Zeiss Meditec: Why This Company Is A Good Choice For 2026
Invesco Global Opportunities Fund Q3 2025 Performance Review
Carl Zeiss Meditec AG (CZMWY) Q4 2025 Earnings Call Transcript
Carl Zeiss Meditec AG (CZMWY) Discusses CEO Transition and Management Continuity Strategy Following Code of Conduct Investigation Transcript
Invesco International Small-Mid Company Fund Q3 2025 Top Contributors And Detractors
Carl Zeiss: The Results After 6M25 Are Encouraging For 2025-2027E
Carl Zeiss Meditec AG (CZMWF) Q2 2025 Earnings Call Transcript
Carl Zeiss Meditec: Recovery Seems Clear Enough
Carl Zeiss: Why I Am So Positive
My 3 Favorite European Stocks To Diversify Your Portfolio
Carl Zeiss: Significant Underperformance, Valuation At Multi-Year Lows
Carl Zeiss Meditec AG (CZMWF) Q3 2024 Earnings Call Transcript
Carl Zeiss Meditec: Slightly Better Valuation, Still A Significant Upside